45th week of 2019 patent applcation highlights part 10 |
Patent application number | Title | Published |
20190336549 | THERAPEUTIC AGENTS AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS - The present disclosure provides therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers. The active ingredients of the therapeutic agents comprise an oncolytic virus that selectively replicate in tumor cells and comprise NK cells. | 2019-11-07 |
20190336550 | GENE THERAPY FOR TREATING PHENYLKETONURIA - Compositions and regimens useful in treating phenylketonuria are provided. The compositions include recombinant adeno-associated virus (rAAV) with a transthyretin enhancer and promoter driving expression of a human phenylalanine hydroxylase. | 2019-11-07 |
20190336551 | Herpesvirus with Modified Glycoprotein B - The present invention is directed to a recombinant herpesvirus comprising a heterologous polypeptide ligand capable of binding to a target molecule and fused to or inserted into glycoprotein B at specific sites. The herpesvirus may comprise more than one ligand, and the additional ligand(s) may be comprised by a modified glycoprotein D and/or modified glycoprotein H. This allows the herpesvirus to target a cell for therapeutic purposes, and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gB, a polypeptide comprising the gB, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed. | 2019-11-07 |
20190336552 | GENETICALLY ENGINEERED VACCINIA VIRUSES - The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination. | 2019-11-07 |
20190336553 | AGENT FOR REDUCING THE NUMBER OF INTESTINAL BACTERIA, FOOD, AND PHARMACEUTICAL PRODUCT - The present invention provides an agent for suppressing the number of intestinal bacteria, which contains an extract and/or crushed product of a plant of the genus | 2019-11-07 |
20190336554 | Edible oral strip or wafer dosage form containing ion exchange resin for taste masking - An edible orally disintegrating tablet dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible orally disintegrating tablet dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration. | 2019-11-07 |
20190336555 | SYNERGISTIC DIETARY SUPPLEMENT COMPOSITIONS FOR IMPROVING BRAIN HEALTH - The present invention relates to synergistic compositions comprising extracts or fractions derived from | 2019-11-07 |
20190336556 | STRAWBERRY PLANT EXTRACT AND USE THEREOF - A strawberry plant extract, an extraction method and a novel use thereof are disclosed. The extraction method comprises: darkly incubating a strawberry plant between the anthesis stage and the first harvest stage, harvesting the strawberry plant with the green-white, white or white-red color of the strawberry fruit, and extracting the strawberry plant with ethanol to obtain the strawberry plant extract. The invention further relates to the use of a strawberry plant extract for the manufacture of a composition, wherein the composition is for inhibiting the secretion of cell promoting inflammatory mediators. | 2019-11-07 |
20190336557 | COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA - A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a | 2019-11-07 |
20190336558 | COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA - A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a | 2019-11-07 |
20190336559 | COMPOSITION FOR TREATING ATOPIC DERMATITIS INCLUDING HERBAL MEDICINE MIXED EXTRACT - Provided are a composition for treating atopic dermatitis including an herbal medicine mixed extract, and more particularly, a pharmaceutical composition, a food composition, a quasi-drug composition, and a cosmetic composition for preventing or treating atopic dermatitis, each composition including a mixed extract of Phellodendri Cortex, Schizonepetae Spica, Sophorae Radix, Glycyrrhizae Radix, Liriopis Tuber, and Radix Rehmanniae Exsiccate or a fraction thereof, and a method of treating atopic dermatitis using the pharmaceutical composition. | 2019-11-07 |
20190336560 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALOPECIA COMPRISING EREMOCHLOA OPHIUROIDES EXTRACT OR FRACTIONS THEREOF AS AN ACTIVE INGREDIENT - The present invention relates to a composition comprising centipede grass extract as an active ingredient for the prevention or treatment of alopecia. Particularly, the centipede grass extract of the present invention increases the expression of hair growth related factors and accelerates hair growth, so that it can be effectively used for the prevention or treatment of alopecia. | 2019-11-07 |
20190336561 | Compositions for Inhibiting PP2A Demethylation - Compositions containing natural and botanical extracts for use in inhibiting one, two, or three of (a)-(c): (a) demethylation of PP2A by PME-1 methylesterase; (b) formation of free radicals and reactive oxygen species; and/or (c) inflammation. These compositions include an extract of one or more botanicals selected from the group consisting of: juniper berry fruit, schisandra fruit, strawberry fruit, avocado seeds, black raspberry seeds, blueberry seeds, celery seeds, cranberry seeds, fennel seeds, grape seeds, guarana seeds, red raspberry seeds, maca root, goldenseal root, turmeric root, magnolia bark, pygeum bark, red raspberry leaf, almond, cocoa powder, | 2019-11-07 |
20190336562 | METHOD AND COMPOSITION FOR A PROTEIN TRANSDUCTION TECHNOLOGY AND ITS APPLICATIONS - A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein. | 2019-11-07 |
20190336563 | COMPOSITIONS AND METHODS FOR MODULATING CILIOGENESIS - Disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject an effective amount of a composition comprising a Notch signaling inhibitor, wherein the modification results in an increase in a number of cilia, an increase in a length of cilia, and/or an increase in a beat frequency of cilia as compared to a control. Also disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject from 0.1 μg/kg to 100 g/kg of a Notch signaling inhibitor. In some embodiments, the methods can be used to treat Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Asthma, Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), or hydrocephalus. | 2019-11-07 |
20190336564 | METHODS AND COMPOSITIONS FOR MODULATING TRANSPORT OF A DRUG - Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein are provided. | 2019-11-07 |
20190336565 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. | 2019-11-07 |
20190336566 | METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY - This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31). | 2019-11-07 |
20190336567 | PHARMACEUTICAL COMPOSITIONS OF WATER SOLUBLE PEPTIDES WITH POOR SOLUBILITY IN ISOTONIC CONDITIONS AND METHODS FOR THEIR USE - The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed. | 2019-11-07 |
20190336568 | ANTIMICOBIAL PEPTIDES FOR INHIBITING DRUG-RESISTANT BACTERIA AND USES THEREOF - Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers. | 2019-11-07 |
20190336569 | PLANT EXTRACT CONTAINING DIKETOPIPERAZINE AND METHOD FOR PRODUCING SAME - A diketopiperazine mixture suitable for mixing with a food or drink and a method for producing the mixture. High-temperature and high-pressure treatment of plant peptides in a liquid allows production of a plant extract containing a high concentration of diketopiperazines including cyclo-leucyl-leucine and cyclo-leucyl-phenylalanine. Diketopiperazines having excellent flavor derived from a plant natural product and can produce a food or drink provided with the functions of the diketopiperazines by directly mixing the diketopiperazines with the food or drink. | 2019-11-07 |
20190336570 | FORMULATIONS OF VANCOMYCIN - Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof. | 2019-11-07 |
20190336571 | NEUROTOXIN FOR USE IN THE TREATMENT OF PERSONALITY DISORDERS - The present invention relates to the use of a neurotoxin, especially botulinum toxin, for use as a medicament in the treatment of a personality disorder and/or a habit and impulse disorder and/or a conduct disorder, as well as to a method for the treatment of a personality disorder and/or of a habit and impulse disorder and/or of a behavioural and emotional disorder with onset usually occurring in childhood and adolescence by administration of the neurotoxin to a patient diagnosed with this disorder. Preferably, the neurotoxin is for use as a medicament in the treatment of an emotionally unstable personality disorder and/or of another personality disorder and/or of a habit and impulse control and/or behavioural and emotional disorders with onset usually occurring in childhood and adolescence, in which the disorder is preferably characterised by emotional instability and impulsivity. | 2019-11-07 |
20190336572 | COMPOSITION AND METHOD FOR ORAL DELIVERY OF STABLE FORMULATIONS OF COBRA VENOM - A composition of sterile cobra venom and a method for its oral administration to provide significant analgesic effects to a human and/or animal are disclosed. Such cobra venom compositions comprise a sterilized solution preserved by the addition of one or more suitable food-grade preservatives. The venom composition may be conveniently administered orally by means of a metered spray device. | 2019-11-07 |
20190336573 | METHODS OF TREATING KAWASAKI DISEASE - The present invention relates to the discovery that etanercept reduces the rate of resistance to intravenous gamma globulin (IVIG) in subjects with acute Kawasaki disease (KD). In certain embodiments, the co-administration of etanercept and IVIG more effectively treats acute KD in subjects older than 12 months than IVIG alone. In other embodiments, the co-administration of etanercept and IVIG ameliorates coronary artery dilation in high risk subjects. | 2019-11-07 |
20190336574 | Use of Peptides That Block Metadherin-SND1 Interaction as Treatment for Cancer - The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells. | 2019-11-07 |
20190336575 | REVERSING DEFICIENT HEDGEHOG SIGNALING RESTORES DEFICIENT SKELETAL REGENERATION - Methods and compositions are provided for the therapeutic use of hedgehog agents, for enhancing bone growth and regeneration in diabetic or pre-diabetic patients, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection or implantation at the site of an injury. | 2019-11-07 |
20190336576 | METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE LUNGS - The present invention relates to methods for treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, status asthmaticus, pneumonia, bronchiectasis, COPD, sarcoidosis, and lung cancer based on reducing airway hyper responsiveness, increasing pulmonary compliance, reducing lung inflammation, reducing inflammatory cell count in bronchoalveolar fluid and reducing cytokine production by administration of a mammalian α- and/or β-defensin. | 2019-11-07 |
20190336577 | METHODS AND COMPOSITIONS RELATING THE TREATMENT OF TUMORS - Described herein are methods and compositions relating to the treatment of a tumor (e.g., schwannoma) by increasing expression of Apoptosis-associated Speck-like protein containing a CARD (ASC) and/or gasdermin D. In some embodiment, the increased expression is provided by means of a vector or construct comprising a nucleic acid encoding Apoptosis-associated Speck-like protein containing a CARD (ASC) and/or gasdermin D operably linked to a Schwann-lineage cell-specific promoter. In some embodiments, the vector is a viral vector. | 2019-11-07 |
20190336578 | Platelet Activation and Growth Factor Release Using Electric Pulses - Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample. In certain embodiments, the growth factor release is not accompanied by clotting within the blood sample. | 2019-11-07 |
20190336580 | Fusion Proteins Containing Insulin-Like Growth Factor-1 and Epidermal Growth Factor and Variants Thereof and Uses Thereof - Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided. | 2019-11-07 |
20190336581 | IMMUNOSTIMULATORY COMPOSITIONS AND USES THEREFOR - Disclosed are compositions and methods for stimulating immune responses. More particularly, these compositions and methods involve the use of an inhibitor of IL-25 function and an immune stimulator that stimulates an immune response to a target antigen for stimulating protective or therapeutic immune responses to a target antigen. The compositions and methods of the present invention are particularly useful in the prevention and treatment of infections and cancers. | 2019-11-07 |
20190336582 | Compositions and Methods for Modulating IL-10 Immunostimulatory and Anti-Inflammatory Properties - The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1: | 2019-11-07 |
20190336583 | COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD - The present disclosure relates to the use of hepcidin, mini-hepcidin, or a hepcidin analogue in therapeutic methods for the treatment and/or prevention of acquired iron overload or other conditions for which iron redistribution or sequestration is helpful. | 2019-11-07 |
20190336584 | METHODS AND COMPOSITIONS FOR TREATING HYPOGLYCEMIC DISORDERS - This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof. | 2019-11-07 |
20190336585 | Method for sustainable human cognitive enhancement - A method of achieving sustainable, general-purpose cognitive enhancement in mentally-healthy adults comprising administering a gene-editing endonuclease complexed with a synthetic guide RNA to lower the population of 5-hydroxytryptamine 2A receptors in the brain. | 2019-11-07 |
20190336586 | Lyophilized Preparation - [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. | 2019-11-07 |
20190336587 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS - Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions. | 2019-11-07 |
20190336588 | USE OF ADAMTS13 FOR TREATING, AMELIORATING AND/OR PREVENTING VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE, ACUTE LUNG INJURY AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME - The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS. | 2019-11-07 |
20190336589 | IMMUNIZING PEPTIDE, METHOD FOR PRODUCING IMMUNIZING PEPTIDE, PHARMACEUTICAL COMPOSITION FOR IMMUNE DISEASE CONTAINING SAME, AND METHOD FOR TREATING IMMUNE DISEASE - The present invention provides a novel immunizing peptide that can induce production of an antibody to a complex of the immunizing peptide and an MHC molecule of a living organism. The immunizing peptide according to the present invention includes a T-cell epitope and an antibody-inducing portion of a target protein. The antibody-inducing portion is at least one of the following amino acid residues in an amino acid sequence of the target protein: one or more contiguous amino acid residues immediately upstream of a N-terminal amino acid residue of the T-cell epitope; and one or more contiguous amino acid residues immediately downstream of a C-terminal amino acid residue of the T-cell epitope. When the immunizing peptide is administered to a living organism, the immunizing peptide induces production of an antibody to a complex of the immunizing peptide and an MHC molecule of the living organism. | 2019-11-07 |
20190336590 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-11-07 |
20190336591 | CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR - Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-α protein and/or a nucleic acid encoding the DN-TNF-α protein. The DN-TNF-α protein and/or a nucleic acid encoding the DN-TNF-α protein can be administered alone or in combination with other agents. | 2019-11-07 |
20190336592 | OMPA AND ASP14 IN VACCINE COMPOSITIONS AND AS DIAGNOSTIC TARGETS - surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention. | 2019-11-07 |
20190336593 | CLOSTRIDIUM DIFFICILE IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - An immunogenic composition containing a | 2019-11-07 |
20190336594 | Vaccine for Protection Against Streptococcus Suis - The present invention pertains to a vaccine comprising an IgM protease antigen of | 2019-11-07 |
20190336595 | INFLUENZA VACCINE - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens. | 2019-11-07 |
20190336596 | UNIVERSAL VACCINE PLATFORM - The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions. | 2019-11-07 |
20190336597 | METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES - The invention relates to methods of generating a robust passive and an active immune response in a subject comprising administering a neutralizing antibody and a pathogen to the subject. The invention also relates to kits and pharmaceutical compositions useful in generating a robust passive and an active immune response in a subject. | 2019-11-07 |
20190336598 | METHODS FOR MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG - The present invention provides compositions and methods for reducing inflammation in the lungs of a mammal that is afflicted by a condition that leads to inflammation in the lungs. The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). | 2019-11-07 |
20190336599 | COMBINATION OF RAMUCIRUMAB AND MERESTINIB FOR USE IN TREATMENT OF COLORECTAL CANCER - The present disclosure relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and merestinib, or a pharmaceutically acceptable salt thereof, and to methods of using the combination to treat certain disorders, such as colorectal cancer, including advanced or metastatic colorectal cancer and/or local colorectal cancer. | 2019-11-07 |
20190336600 | METHODS FOR DETECTING AND REVERSING IMMUNE THERAPY RESISTANCE - Compositions and methods of their use to detect and treat anti-PD1 therapy resistance are provided herein. Compositions that immunospecifically bind and deplete dysfunctional T cells are provided. The dysfunctional T cells that are depleted include CD38 | 2019-11-07 |
20190336601 | Etanercept Formulations Stabilized with Sodium Chloride - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2019-11-07 |
20190336602 | STERILISATION OF S-NITROSOTHIOLS - This invention provides a method of sterilising an S-nitrosothiol, for example S-nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use. | 2019-11-07 |
20190336603 | BIODEGRADABLE LIGHT-ACTIVATABLE DRUG DELIVERY IMPLANT - An implant device includes a polymer tube including an enclosed inner space, and a mixture of a hydrogel and a plurality of nanoparticles within the enclosed inner space. Each of the plurality of nanoparticles includes a shell, payload within the shell, and one or more photothermal agents on a surface of the shell. A wall of the polymer tube includes one or more layers of nanoporous polymer sheets including a plurality of pores. The dimension of the nanoparticles is greater than the dimension of the pores, and the dimension of the payload is smaller than the dimension of the pores. | 2019-11-07 |
20190336604 | Self-Assembled Drug-Loading System And Preparation Method Therefor - Disclosed are a self-assembled drug-loading system containing a hydrophilic phototherapeutic drug and a hydrophobic chemotherapeutic drug, a preparation method therefor and the use thereof for preparing an anti-tumor drug. The self-assembled drug-loading system is a water-soluble complex or water-dispersible nanoparticles formed by means of π-π interaction or hydrophobic interaction between the phototherapeutic drug and the chemotherapeutic drug, wherein the molar ratio of the phototherapeutic drug to the chemotherapeutic drug is 2:1 to 1:10. | 2019-11-07 |
20190336605 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS - Methods for the treatment of a cell proliferation disorder in a subject, involving:
| 2019-11-07 |
20190336606 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS - Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation. | 2019-11-07 |
20190336607 | INJECTABLE PREPARATION - An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s | 2019-11-07 |
20190336608 | CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY - Compositions for nucleic acid delivery are provided which comprise a relatively low amount a permanently cationic lipid or lipidoid, such as a lipid comprising a quaternary ammonium group. The compositions are suitable for the delivery of chemically modified or unmodified DNA or RNA. Moreover, the compositions are suitable for local administration, such as by extravascular injection. | 2019-11-07 |
20190336609 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors - The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds. | 2019-11-07 |
20190336610 | GLUCOSE-SENSITIVE PEPTIDE HORMONES - The present invention relates to a conjugate of the formula P-L-I, wherein P is a peptide hormone effecting the metabolism of carbohydrates in vivo, L is a hydrolysable linker molecule consisting of L | 2019-11-07 |
20190336611 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO - The invention relates to carrier compositions for nucleic acid delivery which comprise a cationic peptide or polymer in combination with a cationic lipid. In a further aspect, the invention relates to nanoparticles comprising a complex of a bioactive cargo material with the peptide or polymer and the lipid. The invention further relates to the preparation and the uses of the nanoparticles. | 2019-11-07 |
20190336612 | BIO-ORTHOGONAL DRUG ACTIVATION - The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives. | 2019-11-07 |
20190336613 | COMPOSITIONS TO TREAT ULTRAVIOLET (UV)-INDUCED SKIN INJURY - This document relates to materials and methods for administering (e.g., topically administering) one or more vascular endothelial growth factor (VEGF) inhibitors to reduce and/or treat ultraviolet (UV)-induced skin injury. For example, compositions including one or more VEGF inhibitors that can be administered (e.g., topically administered) to a mammal to reduce and/or treat UV-induced skin injury following UV exposure are provided. | 2019-11-07 |
20190336614 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES - Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs. | 2019-11-07 |
20190336615 | TUMOR TARGETING CONJUGATES AND METHODS OF USE THEREOF - Various compositions are disclosed. The compositions of conjugates comprising immune-stimulatory compounds are also provided. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating disorders, such as cancer. | 2019-11-07 |
20190336616 | NON-VIRAL NANOPARTICLE-BASED DELIVERY SYSTEM - The present invention concerns a polymeric material for the production of a non-viral nanoparticle. The polymeric material comprises (i) a hydrophilic linear polymer having a first end and a second end, (iii) a cross-linkable cationic polymer covalently bonded to the first end of the hydrophilic linear polymer, and (iii) at least one targeting/penetrating peptide covalently associated to the second end of the hydrophilic linear polymer. Also disclosed herein are nanoparticles produced with these polymeric material, processes for making the polymeric material and the nanoparticles as well as use of the nanoparticles. | 2019-11-07 |
20190336617 | CRISPRs IN SERIES TREATMENT - A method of preventing antibody neutralizing effects with gene editors, by administering a first gene editor to an individual in a treatment for a first virus, administering a second gene editor to the individual in a treatment a second virus, and preventing antibody neutralization to the first and second gene editors. Methods of treating a lysogenic virus or a lytic virus, by administering a first gene editor composition to an individual having a first lysogenic or lytic virus, and inactivating the first virus, administering a second gene editor composition to the individual having a second lysogenic or lytic virus, and inactivating the second virus. An assay method for determining antibody neutralization. | 2019-11-07 |
20190336618 | INTRAETHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS 9 - The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAAV9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone. | 2019-11-07 |
20190336619 | MULTIMODAL PET/MRI CONTRAST AGENT AND A PROCESS FOR THE SYNTHESIS THEREOF - A multimodal PET (positron emission tomography)/MRI (magnetic resonance imaging) contrast agent, a process of synthesizing said PET/MRI contrast agent, and a pharmaceutical formulation comprising said PET/MRI contrast agent are disclosed. The PET/MRI contrast agent comprises a magnetic signal generating core, and a coating portion formed at least partially over a surface of said magnetic signal generating core, wherein the coating portion comprises a plurality of layers, including an inner layer having a functionalized surface, and an outer layer in the form of a radionuclide electrolessly plated layer formed on said functionalized surface. | 2019-11-07 |
20190336620 | NANOMATERIAL AND METHOD OF PRODUCTION OF A NANOMATERIAL FOR MEDICAL APPLICATIONS, SUCH AS MRI OR SERS - A method for producing nanomaterial product which comprises at least one hybrid nanoparticle Gold-metal-Polymer, the polymer comprising at least one biopolymer, the atoms of metal being linked with the atom of Gold, the metal being chosen among: Gd, Co, Eu, Tb, Ce, Mn, Fe, Zn, Cu, the method being realized in an aqueous solvent, without reactive or stabilizer agent, and presenting a step of reducing: tetrachloroauric acid (HAuCl | 2019-11-07 |
20190336621 | RADIOACTIVE COMPOUND FOR DIAGNOSIS OF MALIGNANT MELANOMA AND USE THEREOF - The present invention provides a novel radioactive compound for imaging malignant melanoma and a use thereof as a contrast agent for PET imaging. | 2019-11-07 |
20190336622 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER - The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib). | 2019-11-07 |
20190336623 | TREATMENT OF CANCER CELLS OVEREXPRESSING SOMATOSTATIN RECEPTORS USING OCREOTIDE DERIVATIVES CHELATED TO RADIOISOTOPES - A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination. | 2019-11-07 |
20190336624 | Radioactive Microspheres Made of Nanoporous Glass for Radiation Therapy - Microspheres made of solid glass are used in radiation therapy, wherein the radiotherapeutic radionuclide must be generated in the glass by neutron activation. Microspheres of this type have a high radioactive load, are relatively heavy and contain additional non-therapeutic radionuclides. Additionally, radioactive microspheres made of plastic are used, which can be loaded with radionuclides by chemical means. These microspheres have a lower loading capacity, no additional radionuclides, and are lighter. The therapeutic radionuclide in both cases is Y-90. Microspheres made of nanoporous glass contain the therapeutic radionuclide, have a high loading capacity, require no neutron activation, can be parallel charged with multiple therapeutic and with diagnostic radionuclides, and are very light. It is possible to produce them in a radiochemical laboratory. Microspheres of this type can also be used diagnostically in preparation for therapy. For this purpose, they can be provided in a therapeutically or diagnostically specified quantity and radioactivity. | 2019-11-07 |
20190336625 | ELECTROPORATION OF TISSUE PRODUCTS - The present disclosure provides methods for reducing bioburden on a tissue product, as well as the tissue products produced according to the disclosed methods. In particular, the disclosure relates to methods of electroporating tissue in the presence of one or more bactericides in order to reduce bioburden. The methods allow for reduced exposure to electrical energy and/or bactericide while reducing bioburden. | 2019-11-07 |
20190336626 | Attachable Photocatalytic Device - A photocatalytic device includes one transparent or translucent carrier and at least one photocatalytic film. The carrier is in the form of a sheet with two opposite surface. At least one of the two surfaces of the carrier is at least partially coated with the photocatalytic film. The photocatalytic film is photocatalytic activated by visible light with wavelength>400 nm for providing the antibacterial functionality. In some situation, only the outer surface of the carrier is coated with the photocatalytic film. In other situation, only the inner surface of the carrier is coated with the photocatalytic film. There are situations where both surfaces of the carrier are coated with the photocatalytic film. The carrier has an attaching mechanism for attaching the carrier to the external solid object, and the carrier is attachable to and detachable from the external solid object hands of a user without using a tool. | 2019-11-07 |
20190336627 | DEVICE AND METHOD FOR DISINFECTING CPAP COMPONENTS USING CHEMICALLY REACTIVE SUBSTRATE - This disclosure relates to a device and method for disinfecting CPAP components using a chemically reactive substrate. Specifically, the device and method are used to disinfect CPAP components (or, CPAP equipment), including the various parts of a CPAP system, such as hoses, masks, pillows, couplings, humidifiers, etc., that require frequent cleaning and disinfecting. An exemplary device includes, among other things, a chamber, an ultraviolet (UV) light configured to emit UV light within the chamber, and a substrate chemically reactive to the UV light. Exposing the substrate to UV light releases free radicals which are configured to destroy bacteria, mold, and fungus, as well as eliminate odor. The free radicals may be circulated within the chamber and consequently within the CPAP components that are placed within the chamber to provide a thorough disinfection. | 2019-11-07 |
20190336628 | ULTRAVIOLET LIGHT-STERILIZED AND ILLUMINATING CASTER WHEEL SETS - A caster wheel assembly includes a swivel frame and a caster wheel rotatably coupled to the swivel frame via an axle. The swivel frame can include a rotatable shaft enabling rotation of the wheel and at least one light emitting diode (LED) disposed on a surface of the swivel frame to at least partially illuminate ambient surroundings. The LED may be an ultraviolet (UV) LED disposed on the surface of the swivel frame to interface a portion of the caster wheel thereby enabling UV light emitting from the LED to sterilize pathogens colonizing the caster wheel. The LED may be disposed on an external surface of the swivel frame to at least partially illuminate ambient surroundings. Upon an adjustable predetermined time or distance of motion, the wheel may be braked for ultraviolet light to sterilize pathogens colonizing the caster wheel and released following an adjustable predetermined time. | 2019-11-07 |
20190336629 | Ultraviolet-Based Bathroom Surface Sanitization - A solution for cleaning and/or sterilizing one or more surfaces in a bathroom is provided. The sterilization can be performed using ultraviolet sources, which can emit ultraviolet radiation directed onto the surface(s). The cleaning can be performed using a fluid, such as water, that is flowed over the surface(s). The surface(s) can include at least a seat of a toilet and/or other surfaces associated with the toilet. | 2019-11-07 |
20190336630 | Decontamination Method and Apparatus - Provided is an apparatus for disinfecting objects of various shapes and sizes. The apparatus includes a housing enclosing a disinfecting chamber, and an ultraviolet light source arranged to emit ultraviolet light into the disinfecting chamber to deactivate at least a portion of a biologically-active contagion present on the object. A peripheral wall of the housing that extends about a portion of the disinfecting chamber comprises an ultraviolet-reflective material so that the ultraviolet light impinging on the peripheral wall is reflected generally away from the peripheral wall and toward an interior of the disinfecting chamber. A door is adjustable between open and closed orientations. A floor at the bottom of the disinfecting chamber includes an ultraviolet-reflective surface that reflects the ultraviolet light impinging on the floor generally away from the floor toward the interior of the disinfecting chamber. | 2019-11-07 |
20190336631 | Anti-Bacterial Photocatalytic Coating Apparatus And Process - An anti-bacterial photocatalytic coating apparatus includes a chassis and a container containing an anti-bacterial photocatalytic coating liquid. There is a means mounted on the chassis for applying plasma-based surface activation unto a stationary surface underneath the chassis. There is also a means mounted on the chassis for spraying the anti-bacterial photocatalytic coating liquid on the surface underneath the chassis. A third means mounted on the chassis for shining UV light onto the surface sprayed with the anti-bacterial photocatalytic coating liquid. Optionally, there is a means mounted on the chassis for baking the surface sprayed with the anti-bacterial photocatalytic coating liquid. The plasma-based surface activation may be replaced with the spraying of a non-photocatalytic prime coating. The equivalent anti-bacterial photocatalytic coating processes for coating stationary surface are also introduced. | 2019-11-07 |
20190336632 | SYSTEM AND APPARATUS THEREOF FOR DESTROYING PATHOGENS ASSOCIATED WITH FOOTWEAR - An apparatus for destroying pathogens includes a platform and an LED matrix panel. The platform has a portion configured to permit passage of ultraviolet light therethrough. The LED matrix panel is disposed below the portion of the platform and includes a grid and a plurality of discreetly-controlled, ultraviolet light LEDs (UV LEDs). The grid defines a plurality of cells. Each UV LED is associated with one cell such that the cells direct the ultraviolet light emitted by the UV LEDs upwardly through the portion of the platform to sanitize an object supported on the portion of the platform. | 2019-11-07 |
20190336633 | METHOD FOR PREVENTING DEPOSITION OF CONTAMINATION ON CERTAIN PARTS OF INSTRUMENTS PLACED IN A STEAM AUTOCLAVE DURING THE STERILIZATION PROCESS. - Method for preventing deposition of contamination on certain parts of instruments placed in a steam autoclave during the sterilization process, characterized in that the surface of an instrument that is meant to be kept clean, is covered and placed in the autoclave, and whereby by means of the method of attachment and or shape of the cover, the inner side of the cover facing the surface to be kept clean is held at a specific distance from said surface during the autoclaving process, with a limit value between a minimum of 0.2 mm and a maximum of 0.5 mm. | 2019-11-07 |
20190336634 | HOUSING APPARATUS - This accommodation device is for performing sterilization through irradiation with ultraviolet light. The device is provided with an ultraviolet light lamp for emitting ultraviolet light, electric wires for supplying power to the ultraviolet light lamp, socket parts for supporting the ultraviolet light lamp, and a housing in which the ultraviolet light lamp is disposed, wherein: the socket parts have formed therein first opening portions which are open to the inside of the housing, and second opening portions which are in fluid connection with the first opening portions and through which the electric wires pass; and the housing has formed therein third opening portions which guide the electric wires to the outside and which are in fluid connection with the second opening portions. | 2019-11-07 |
20190336635 | MAGNETIC SEPARATION USING NANOPARTICLES - Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn | 2019-11-07 |
20190336636 | DISSOLVABLE EFFERVESCENT TOILET DEODORIZER AND METHOD OF USE - A dissolvable effervescent toilet deodorizer includes a combination of citric acid, sodium bicarbonate, and essential oils. In one method of use, a user would drop the dissolvable effervescent toilet deodorizer into the toilet bowl just prior to using the toilet. Once dropped into the toilet bowl, the dissolvable effervescent deodorizer begins to dissolve and effervesce. As a result of the effervescence, the dissolution occurs more rapidly and also disperses the deodorizer/scent into the toilet water and air to more effectively neutralize and/or prevent malodors. | 2019-11-07 |
20190336637 | SCENT DISPENSER/ABSORBER - A scent absorber/dispenser is disclosed. The scent dispenser/absorber has a housing having a base and a cover that cooperate to form an interior chamber of the housing. The dispenser can take the form of an individual dispenser/absorber housing, or a dual dispenser absorber made of two housings are arranged in piggyback (i.e., back-to-back) fashion. The interior chamber of each scent dispenser/absorber is configured to receive scent means adapted to perform either a scent-absorbing function or a scent-emitting function. To use the scent dispenser/absorber, the cover of one or more housings can be moved away from its respective base to expose diffusion ports in a sidewall of the base, thereby permitting desirable scents to flow from the corresponding scent means of the one or more housings to the surrounding environment, or undesirable odors in the surrounding environment to flow into the aforesaid scent means. | 2019-11-07 |
20190336638 | SCENT DIFFUSER - Scent diffusers (e.g., air fresheners) having adjustable scent diffusion rates may comprise scent intensity adjustment configurations for adjusting the intensity of a fragrance material emitted from the scent diffusers. In certain embodiments, the scent intensity adjustment configuration may take the form of slidable planar scent panels saturated with fragrance composition that may be moved into and out of a hollow body portion. When positioned substantially within the hollow body portion, the scent panels emit fragrance composition at a first rate, and when positioned substantially outside of the hollow body portion, the scent panels emit fragrance at a second rate, faster than the first rate. Alternatively, a scent diffuser may have a body portion containing a scent panel, wherein the body portion has a plurality of ventilation openings to control the rate of fragrance composition diffusion by rotating an adjustment panel to selectively block the ventilation openings of the body portion. | 2019-11-07 |
20190336639 | APPARATUS FOR DELIVERING A VOLATILE MATERIAL - An apparatus for delivering a volatile material in a continuous manner is disclosed. The apparatus includes a delivery engine having a reservoir for containing a volatile material; a rupturable substrate secured to the reservoir; a rupture element positioned adjacent to the rupturable substrate; and a breathable membrane enclosing the reservoir, rupturable substrate and rupture element. In some embodiments, the apparatus includes a housing having a notch for compressing the rupture element and breaching the rupturable substrate as it is inserted into the housing. | 2019-11-07 |
20190336640 | POLYURETHANE-HYDROGEL COMPOSITION COMPRISING CHLORHEXIDINE - The invention is directed to a composition comprising: a polyurethane substrate; a hydrogel forming polymer on at least one of the two faces of the polyurethane substrate; and chlorhexidine on the at least one face comprising the hydrogel forming polymer; wherein the hydrogel polymer is covalently linked to the polyurethane substrate. The invention is also directed to a dressing in comprising the composition and to a process for the preparation of the composition, the process comprising the following steps: a) in impregnating at least one face of a polyurethane substrate with a solution comprising a reactive diolefin and a free radical initiator; b) extracting the polyurethane from the solution and, after drying, immerging the polyurethane in a solution containing the initiator catalyst and the hydrogel forming polymer to obtain PU covalently bond to a hydrogel forming polymer; c) extracting the polyurethane-hydrogel composition and drying in air; d) immerging the product of step iii) into an aqueous solution of chlorhexidine; e) collecting the polyurethane-hydrogel-chlorhexidine product from the solution and drying the obtained composition in air. | 2019-11-07 |
20190336641 | WOUND DRESSING MATERIALS - A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials. | 2019-11-07 |
20190336642 | SURGICAL SEALANT - A surgical sealant consisting of (1) a first agent comprising a gelatin derivative, wherein the gelatin derivative (a) has a weight average molecular weight of from 10,000 to 50,000; (b) has a hydrophobic group bonded thereto, the hydrophobic group being an alkyl group having 6 to 18 carbon atoms; (c) has a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and (d) comprises a structure represented by the following formula: GltnNH—CHR | 2019-11-07 |
20190336643 | MEDICAL HYDROGEL - The present application relates to a medical hydrogel comprising nanofibrillar cellulose, wherein the hydrogel has a viscosity in the range of 2500-9000 Pa·s and a water retention value in the range of 30-100 g/g. The present application also relates to a method for preparing the medical hydrogel The present application relates to the medical hydrogel for use for treating wounds. | 2019-11-07 |
20190336644 | CONDUCTIVE BIOMATERIAL FOR ENHANCEMENT OF CONDUCTION IN VITRO AND IN VIVO - The present disclosure relates to a biocompatible, electrically conductive polymer capable of carrying the electrical potential of a cardiac impulse. The present disclosure also relates to treatments using the electrically conductive polymer, such as for atrial fibrillation. | 2019-11-07 |
20190336645 | RECOMBINANT POLYPEPTIDES, COMPOSITIONS, AND METHODS THEREOF - The present disclosure provides recombinant polypeptides, homodimeric and heterodimeric proteins comprising the recombinant polypeptides, nucleic acid molecules encoding the recombinant polypeptides, and vectors and host cells comprising the nucleic acid molecules. The present disclosure also provides compositions comprising the recombinant polypeptides and methods of making and using the recombinant polypeptides. | 2019-11-07 |
20190336646 | SYSTEM AND METHOD FOR HARVESTING AUTOLOGOUS ADIPOSE TISSUE - A triple-chambered container includes: a main container body with a first chamber which has an opening at its distal end; a main barrel formed and movable longitudinally within the first chamber, the main barrel defining therein a second chamber for receiving fluids, the main barrel further having an apertured stopper at its distal end; a second barrel formed within the main barrel, the second barrel defining a third chamber for receiving fluids, the second barrel being movable longitudinally within and with respect to the main barrel, the second barrel having a distal end which is engageable and disengageable with the apertured stopper; a shaft adapted to fit within the second barrel, the shaft being movable longitudinally within and with respect to the second barrel, the shaft having a distal end which is engageable and disengageable with an aperture in the second barrel; a device for controlling engaging and disengaging of the distal end of the shaft with the aperture of the second barrel. The first chamber, the second chamber and the third chamber may be selectively moved to receive and discharge fluids with respect to one another. | 2019-11-07 |
20190336647 | THIN FILM INTERPOSITION OF BASEMENT MEMBRANE SCAFFOLDS - Disclosed are compositions and methods of making basement membrane constructs having interior or luminal volumes. The interior or luminal volumes may be in the form of vascular networks for liquid (e.g., blood) or gas perfusion. The interior spaces may also contain cells, such as epithelial cells. Also disclosed are tissues and organs, and methods of making thereof, comprising basement membrane constructs. | 2019-11-07 |
20190336648 | BONE-PROMOTING THERMORESPONSIVE MACROMOLECULES - Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases. | 2019-11-07 |
20190336649 | CRYOGEL 3D SCAFFOLDS AND METHODS FOR PRODUCING THEREOF - A method of producing a cryogel-based multicompartment 3D scaffold is herein disclosed. The method comprises the steps of: a) providing a first frozen polymeric layer on a refrigerated support kept at subzero temperature; b) providing subsequent polymeric layers to obtain a stack of polymeric layers by possibly modulating the subzero temperature of the refrigerated support; c) optionally incubating the final polymeric structure at subzero temperature; and d) placing the produced cryogel at a temperature above 0° C., the method being characterized in that each subsequent layer i) is deposited on the previous one after freezing of this latter; ii) is deposited on the previous one before the complete polymerization of this latter; and iii) is deposited with a temperature higher than the freezing temperature of the previously deposited layer. Cryogel scaffolds obtained from the method of the invention are also disclosed. | 2019-11-07 |